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ORIGINAL ARTICLE / ÖZGÜN ARAŞTIRMA
Evaluation of serum cortisol and dehydroepiandrosterone sulphate levels in parkinson 
patients with and without postural instability
Postural instabilitesi olan ve olmayan parkinsonlu hastalarda serum kortizol ve 
dehidroepiandrosteron sülfat düzeylerinin değerlendirilmesi
Murat Gültekin¹, Recep Baydemir², Sevda İsmailoğulları¹, Fatih Tanrıverdi³, Meral Mirza¹
ÖZET
Amaç:  Parkinson  hastalığı  (PH)  ikinci  sıklıkta  görülen 
nörodejeneratif bir hastalıktır. Hastalık süresince otonom 
disfonksiyon ile beraber pek çok nöroendokrin mekaniz-
mada  bozukluk  meydana  gelmektedir.  Bu  çalışmadaki 
amaç; postural instabilitesi (Pİ) olan orta ve ileri evredeki 
idiopatik PH’li hastalarda serum kortizol ve dehidroepi-
androsteron sülfat (DHEAS) değerlerini değerlendirmek-
tir.
Yöntemler:  Çalışmaya  her  biri  30  bireyden  oluşan  Pİ 
olan hastalar, erken evre Pİ olmayan hastalar ve kont-
rol grubu alındı. Hastaların sabah açlık serum kortizol ve 
DHEAS değerleri ölçüldü.
Bulgular: Serum kortizol düzeyi Pİ olan ileri evre hasta 
grubunda DHEAS ise Pİ olmayan erken evre hasta gru-
bunda anlamlı olarak yüksek bulundu. 
Sonuç: Bu durum; PH’de görülen ilerleyici nörodejene-
rasyona sekonder olarak ortaya çıkan nöroendokrin ce-
vabın yansıması olarak değerlendirildi. Elde edilen veriler, 
PH’de orta ve ileri evrede hastalık patofizyolojisinin daha 
iyi anlaşılmasına ve hastalar için gelecekte ilave tedavi 
seçeneklerinin oluşturulması yönünden katkı sağlamak-
tadır.
Anahtar kelimeler: Parkinson hastalığı, postural instabi-
lite, kortizol, dehidroepiandrosteron sülfat
ABSTRACT
Objective: Parkinson’s disease (PD) is the second most 
common  neurodegenerative  disease.  During  PD  many 
disorders occur in the neuroendocrine mechanism along 
with autonomic dysfunction. The aim of this study was to 
evaluate  the  values  of  cortisol  and  dehydroepiandros-
terone sulphate (DHEAS) in idiopathic PD patients with 
postural instability (PI) in the medium and advanced stag-
es of the disease. 
Methods: Three groups were included in this study; pa-
tients with PI, patients without PI and control subjects. 
Each of the groups consisted of 30 patients. The fasting 
serum cortisol and DHEAS values of patients were ob-
tained. 
Results: Serum cortisol levels were significantly higher 
in patients with PI in the advanced stage of PD, whereas 
DHEAS levels were significantly higher in patients without 
PI in the early stage. 
Conclusion: This situation was evaluated as the reflec-
tion of neuroendocrine response that occurred secondary 
to the progressive advancing neurodegeneration seen in 
PD patients. The data obtained may contribute to a better 
understanding of the pathophysiology of PD that in inter-
mediate and advanced stages. In addition, our findings 
may help in establishing new treatment options for PD pa-
tients in the future. J Clin Exp Invest 2014; 5 (3): 376-380
Key words: Parkinson’s disease, postural instability, cor-
tisol, dehydroepiandrosterone sulphate
INTRODUCTION
Parkinson’s disease (PD) has a chronic neurode-
generative and progressive period. During PD, in 
addition to common autonomic dysfunction, many 
changes occur in the neuroendocrine mechanism 
including circadian rhythm in the dopaminergic sys-
tem of the central nervous system (CNS) [1].Gültekin M, et al. Serum cortisol and DHEAS levels in parkinson 377
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Postural instability (PI) generally shows an in-
crease  towards  the  chronic  stage  of  the  disease 
and affects daily life negatively by preventing pa-
tients from the having independent motor skills. In 
previous studies it was reported that in the first two 
years of PD 34% of patients had PI, while in the 
tenth year of 71% had PI [2].
Cortisol and dehydroepiandrosterone (DHEA) 
are steroid type hormones that significantly affect 
energy metabolism, the immune system and stages 
of ageing. Although the importance of dehydroepi-
androsterone sulphate, which is an esterified form 
of DHEA, has been identified in the elderly popu-
lation,  it’s  the  physiologic  effects  have  not  been 
explained  clearly  yet.  Neurosteroids  are  effective 
in the modulation of neurotransmitter activity, neu-
rotrophic and neuroprotective functions. Consistent 
with this, a few studies have been conducted on 
neurodegenerative  diseases  and  changes  in  the 
levels of neurosteroids to determine if there is an 
association among them [3].
In most previous studies cortisol levels were 
found to be high in PD patients. This situation has 
been considered as a process of advancing neuro-
degeneration in PD [4]. In contrast, the data about 
DHEAS, which is thought to be neuroprotective, are 
not clear enough [5,6].
The aim of this study is to evaluate serum cor-
tisol and DHEAS values in idiopathic PD patients 
who  have  postural  instability  (PI)  (Hoehn&Yahr 
stage 3-4) and who do not have PI (Hoehn&Yahr 
stage 1-2) by comparing them with a healthy group.
METHODS
Patients and laboratory methods
In this study a total of 90 people, who were divided 
into three groups consisting of 30 people, each were 
evaluated. The fasting serum cortisol and DHEAS 
levels of PD patients with PI (Hoehn&Yahr stage 
3-4),  PD  patients  without  PI  (Hoehn&Yahr  stage 
1-2) and the healthy control group were measured.
The patient groups and control group were dis-
tributed into available groups in terms of age and 
gender. The exclusion criteria fort the patient groups 
were as follows: having any kind of endocrine dis-
order (Diabetes mellitus, Addison’s syndrome, hy-
pothyroid,  hyperthyroid  etc.),  secondary  Parkin-
sonism, not being in the 40-80 age range, duration 
of PD of less than two years, use of anti-epileptic 
drugs, malignancy, polyneuropathy or having a psy-
chiatric disease, chronic renal failure or having a 
cerebrovascular disease past history, motor disor-
der due to spinal trauma, and receiving dementia or 
corticosteroid treatment.
The samples were collected in the morning, at 
08.00 am, into sample tubes containing clot acti-
vator and gel without anticoagulants. Cortisol and 
DHEAS were analyzed with a DXI 800 immunoana-
lyzer (Beckman Coulter Inc, USA) using chemilu-
minescant reactives. The obtained data were com-
pared statistically by considering age and disease 
period among the groups. Ethical approval was ob-
tained for this study.
Statistical analysis
Normal distribution of data was examined by the 
Shapiro-Wilk test. In the comparison of two groups 
(postinst-hassure)  the  Mann-Whitney  U  test  was 
used when the data were not distributed normally. 
In the comparison of three groups, for normally dis-
tributed data single direction variance analysis, was 
used and for non-normally distributed data Kruskal-
Wallis analysis was used. In case of finding a dif-
ference as a result of Kruskal-Wallis analysis, the 
nonparametric  Student-Newman-Keuls  test  was 
used as a multiple comparison test. In comparison 
of  categorical  variables  the  Chi-square  test  was 
used and a p<0.05 value was considered statisti-
cally important. IBM SPSS Statistics 21.0 program 
was used for the statistical analysis.
RESULTS
No statistical difference was observed between the 
study groups in terms age, gender and disease pe-
riod. The average age was found as 69.2 years in 
the group with PI, as 66.7 years in the group without 
PI and as 68.4 years in the control group (Table 1).
In this study, serum cortisol levels in patients 
with PD were higher than those in the control group. 
Serum  cortisol  was  found  as  16.54  µg/dl  in  the 
group with PI (Hoehn&Yahr stage 3-4), as 11.69 µg/
dl in the group without PI (Hoehn&Yahr stage 1-2) 
and as 10.13 µg/dl in the control group. According 
to these data the level of cortisol was found to be 
higher in the PD with PI group and this result was 
statistically significant (p=0.038). Moreover, the lev-
el of cortisol in the without PI group was found to be 
higher than that of the control group but this result 
was not statistically significant (p=0.207) (Figure 1).Gültekin M, et al. Serum cortisol and DHEAS levels in parkinson 378
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Postural instability (+)
(Hoehn&Yahr  stage  3-4) 
(n=30)
Postural instability (-)
(Hoehn&Yahr  stage  1-2) 
(n=30)
Controls
(n=30)
Age (mean ± SD) 69.2±10.9 66.7±7.9 68.4±8.2
Sex (M/F) 16/14 16/14 17/14
Disease duration, years
(mean ± SD)
5.5±3.2 4.5 ±2.1 -
Figure 2. The average serum DHEAS values in patients 
and control group
PI (+): PD patients with postural instability (Hoehn&Yahr 
stage 3-4)
PI (-): PD patients without postural instability (Hoehn&Yahr 
stage 1-2)
DISCUSSION
When compared to the control group, the data from 
our study, suggest that cortisol levels are high es-
pecially in patients with PI in the moderate and se-
vere stage (Hoehn & Yahr stage 3-4). This situation 
was evaluated as the reflection of neuroendocrine 
response that occurred secondary to the progres-
sive neurodegeneration seen in PD. In patients with 
advanced disease, a tendency progress towards a 
rise in cortisol levels in response to chronic stress 
was  observed.  In  addition,  the  level  of  DHEAS 
which  is  considered  to  be  neuroprotective,  was 
found to be the highest in the early stages of dis-
ease  (Hoehn&Yahr  stage  1-2).  This  finding  sug-
gests  that neuroprotective  mechanisms  are  more 
active in the early stage of PD.
Neuroinflammation along with oxidative stress, 
mitochondrial dysfunction and abnormal protein ag-
gregation play an important role in PD pathophysi-
ology. In classical neurodegenerative diseases like 
PD, a disorder occurs in the hypothalamo-hypoph-
yseal-adrenal cycle and a change in cortisol level 
is  observed  [4,7,8].  In  most  studies  a  significant 
Table 1. The demo-
graphic  features  of 
individuals in patient 
groups  and  control 
group
Figure 1. The average serum cortisol values in patients 
and control group.
PI (+): PD patients with postural instability (Hoehn&Yahr 
stage 3-4)
PI (-): PD patients without postural instability (Hoehn&Yahr 
stage 1-2)
The level of DHEAS was found to be higher in 
patients with PD, as was so for cortisol, but it was 
lowest in the control group. The level of DHEAS in 
the group with PI (Hoehn&Yahr stage 3-4) was found 
as 94.12 µg/dl, in the group without PI (Hoehn&Yahr 
stage 1-2) as 99.01 µg/dl and in the control group 
as 61.55 µg/dl. However it was found, in particular, 
to be highest in the group without PI at a relatively 
early stage (stage 1-2) of PD and this result was 
also found to be statistically significant (p=0.046). 
Additionally it was found to be higher in the group 
with PI than in the control group and this result was 
found to be statistically significant (p=0.024) (Figure 
2). According to these data the DHEAS levels were 
found to be higher in the relatively early stages of 
PD in the group without PI.
In this study, compared to the control group, 
both the levels of cortisol and DHEAS were found 
to be significantly higher in the PD patient group 
(p<0.05). Gültekin M, et al. Serum cortisol and DHEAS levels in parkinson 379
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increase in cortisol level was observed. It changes 
according to brain steroid condition, lifelong stress 
and disease. Increased steroid levels are known to 
be neurotoxic to the brain. It was reported that in-
creased cortisol levels have a negative effect on the 
synthesis of many neurotransmitter including dopa-
mine and serotonin by causing hippocampal atro-
phy and disorder cognitive functions [9].
It was reported 30 years ago that steroids are 
produced locally in CNS. The most commonly found 
neurosteroids in the CNS system are pregnenolone 
and DHEA [10]. Neurosteroids are effective in the 
modulation, neurotrophic and neuroprotective func-
tions of neurotransmitter activity. As a result of this, 
they take part in many processes such as neural 
development, increasing synapse formation, plas-
ticity, emotion-situation, memory, sexual behaviour, 
sleeping, digestion, aggression during stress, my-
elination and immune response [11].
DHEAS, which is synthesized in the glial cells 
locally,  has  a  neuroprotective  effect  against  free 
radicals  that  occur  during  the  oxidative  period  in 
chronic  neurodegenerative  diseases  like  PD  (6). 
However,  the  information  about  neurosteroids  is 
mostly dependent on studies done on animals and 
only a few clinical studies have been conducted on 
humans. In the study done on Parkinsonian mon-
keys  with  MPTP  (1-methyl-4-phenyl-,2,3,6  tetra-
hydro pyridine) lesion, it was shown that DHEAS 
regulated locomotor activity [12]. 
There  are  only  a  few  studies  that  analyse 
neurosteroid synthesis changes in PD patients. In 
many studies the serum DHEAS levels of PD pa-
tients were found to be higher than those in control 
groups. It was reported that DHEAS plays a protec-
tive role in the hippocampus and neocortex region 
against  the  neurotoxic  effects  of  glutamate  ana-
logues and corticoids. Also, it was shown that giving 
DHEAS decreases plasma cortisol levels and has 
the capacity to make structural changes in receptor 
proteins such as NMDA and dopamine [13,14]. In 
another study, patients with systemic lupus erythe-
matosus that were given oral DHEAS administra-
tion for 3-6 months were shown to have decreased 
disease  activity  and  a  reduction  in  corticosteroid 
therapy treatments [15]. 
Many symptoms such as pain, change of mood 
and autonomic dysfunction can affect cortisol and 
neurosteroid level in PD patients. This situation was 
not dealt with in our study and was considered as 
a restrictive factor. In addition, the small number of 
patients included in the study can also be accepted 
as a restrictive factor.
Our study shows that there is a increase in the 
cortisol levels of PD patients in the advanced stage. 
The treatment aimed at reducing, increased cortisol 
levels can slow the speed of the disease in neuro-
degenerative diseases like PD. The level of DHEAS 
was found to be higher in the early phase of the 
disease. In order to understand the effect of DHEAS 
in PD patients better, more studies are needed in 
a large number of patients in which the disease is 
considered according to stages. As a result of this 
study we believe that the data obtained may con-
tribute to a better understanding of the pathophysi-
ology of the intermediate and advanced stages of 
PD. Also, our findings may help in establishing new 
treatment options for PD patients in the future.
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